CA
NZ
UK
AU
IND
US
…
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Immuron Ltd develops oral polyclonal antibody therapies and consumer products derived from bovine colostrum to prevent or treat gastrointestinal and infectious diseases. Long-term growth may be driven by commercialization of its OTC gastrointestinal product, progress of clinical-stage candidates and licensing or distribution expansion. Investors may find the company attractive because its non-antibiotic platform could produce recurring consumer revenue while supporting pipeline value.
Key risks include clinical and regulatory failure for therapeutic candidates, manufacturing and scale-up challenges for biological products and funding constraints that could dilute shareholders or delay development.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -4.36M | -5.22M | -6.94M | -3.79M | -2.85M |
| Net income | -3.75M | -5.22M | -6.94M | -3.79M | -2.59M |
| Selling general administrative | - | 4.48M | 4.56M | 4.15M | 3.47M |
| Selling and marketing expenses | - | 3.45M | 2.03M | 0.93M | 0.42M |
| Gross profit | 4.87M | 4.77M | 3.34M | 1.31M | 0.52M |
| Reconciled depreciation | - | 0.05M | 0.05M | 0.05M | 0.04M |
| Ebit | - | -5.36M | -5.22M | -3.61M | -3.12M |
| Ebitda | -4.63M | -5.31M | -5.17M | -3.57M | -3.05M |
| Depreciation and amortization | - | 0.05M | 0.05M | 0.05M | 0.06M |
| Operating income | -4.63M | -5.34M | -5.80M | -3.57M | -3.12M |
| Other operating expenses | 12.18M | 12.63M | 10.70M | 5.21M | 3.88M |
| Interest expense | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.14M | 0.33M | 0.12M | 0.02M |
| Net interest income | - | 0.13M | 0.32M | 0.11M | 0.02M |
| Income tax expense | -0.61M | - | -0.76M | -0.31M | -0.26M |
| Total revenue | 7.55M | 7.29M | 4.90M | 1.80M | 0.77M |
| Total operating expenses | 9.50M | 10.11M | 9.14M | 4.72M | 3.64M |
| Cost of revenue | 2.68M | 2.52M | 1.57M | 0.50M | 0.24M |
| Total other income expense net | 0.27M | 0.13M | -1.14M | -0.49M | 0.26M |
| Net income from continuing ops | - | -5.22M | -6.94M | -3.79M | -2.85M |
| Net income applicable to common shares | - | - | - | -3.79M | -2.85M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 12.99M | 10.09M | 15.55M | 21.99M | 24.86M |
| Other current assets | 0.26M | 1.55M | 0.11M | 0.16M | 0.57M |
| Total liab | 1.99M | 2.06M | 2.84M | 2.37M | 1.68M |
| Total stockholder equity | 11.01M | 8.03M | 12.71M | 19.62M | 23.18M |
| Other current liab | 0.44M | 0.83M | 2.01M | 0.04M | 0.75M |
| Common stock | 95.66M | 88.87M | 88.50M | 88.44M | 88.44M |
| Capital stock | - | 88.87M | 88.50M | 88.44M | 88.44M |
| Retained earnings | -85.13M | -82.48M | -78.97M | -72.06M | -68.43M |
| Other liab | - | - | - | 0.00M | 0.00M |
| Other assets | - | - | - | 1.22M | 0.96M |
| Cash | 9.02M | 2.83M | 11.66M | 17.16M | 22.11M |
| Total current liabilities | 1.79M | 1.97M | 2.70M | 2.22M | 1.50M |
| Current deferred revenue | - | - | 1.45M | 0.70M | - |
| Net debt | -9.02M | -2.71M | -11.48M | -16.97M | -21.90M |
| Short term debt | - | 0.05M | 0.04M | 0.29M | 0.03M |
| Short long term debt total | - | 0.12M | 0.17M | 0.19M | 0.21M |
| Other stockholder equity | 96.14M | - | - | 3.24M | 23.18M |
| Property plant equipment | - | - | - | 0.20M | 0.23M |
| Total current assets | 12.80M | 9.98M | 14.73M | 20.41M | 23.67M |
| Long term investments | - | - | 0.00M | 0.16M | - |
| Net tangible assets | - | - | - | 19.62M | 23.18M |
| Short term investments | - | 3.04M | 0.00M | 1.83M | - |
| Net receivables | 1.25M | 0.79M | 1.39M | 0.42M | 0.66M |
| Inventory | 2.27M | 1.77M | 1.58M | 0.84M | 0.33M |
| Accounts payable | 1.35M | 1.53M | 0.65M | 1.19M | 0.72M |
| Accumulated other comprehensive income | 0.48M | 1.64M | 3.17M | 3.24M | 3.17M |
| Non currrent assets other | - | 0.00M | 0.67M | 1.22M | 0.96M |
| Non current assets total | 0.19M | 0.11M | 0.82M | 1.58M | 1.18M |
| Capital lease obligations | - | 0.07M | 0.17M | 0.19M | 0.21M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -2.90M | 0.33M | -2.62M | 0.01M |
| Change to liabilities | - | - | - | 0.69M | 0.29M |
| Total cashflows from investing activities | 2.97M | -2.90M | 0.33M | -2.62M | 0.01M |
| Net borrowings | - | -0.07M | -0.02M | -0.04M | -0.04M |
| Total cash from financing activities | 6.35M | 0.20M | 0.00M | -0.04M | -0.04M |
| Change to operating activities | - | - | - | 1.26M | -0.49M |
| Net income | -3.75M | -5.22M | -6.94M | -3.79M | -2.59M |
| Change in cash | 6.34M | -8.83M | -5.50M | -4.95M | -2.94M |
| Begin period cash flow | 2.68M | 11.66M | 17.16M | 22.11M | 25.05M |
| End period cash flow | 9.02M | 2.83M | 11.66M | 17.16M | 22.11M |
| Total cash from operating activities | -3.00M | -6.14M | -5.88M | -2.60M | -2.55M |
| Issuance of capital stock | - | 0.40M | 0.02M | 0.00M | 0.00M |
| Depreciation | - | 0.05M | - | 0.05M | 0.04M |
| Other cashflows from investing activities | 2.97M | -2.90M | 0.33M | 0.12M | 0.02M |
| Dividends paid | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | - | 0.48M | -0.19M | -0.78M | 0.28M |
| Change to account receivables | - | -0.56M | -0.96M | 0.23M | -0.34M |
| Other cashflows from financing activities | -0.16M | -0.13M | -0.01M | -0.01M | -0.01M |
| Change to netincome | - | - | - | -0.26M | -0.05M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.01M | 0.01M |
| Change in working capital | - | -0.52M | -0.97M | 1.40M | -0.27M |
| Stock based compensation | - | 0.30M | - | 0.23M | 0.09M |
| Other non cash items | 0.76M | -0.75M | 2.03M | 0.47M | 2.55M |
| Free cash flow | -3.00M | -6.14M | -5.88M | -2.60M | -2.56M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IMRN Immuron Ltd ADR |
0.02 1.79% |
0.88 | - | - | 1.30 | 1.28 | 0.69 | 0.77 |
| NVO Novo Nordisk A/S |
2.50 6.21% |
42.69 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.19 3.43% |
548.95 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-29.09 2.99% |
944.27 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jerry Kanellos Ph.D. | Chief Operating Officer | 1961 |
| Mr. Steven George Lydeamore CPA, CPA, M.B.A., MBA | Chief Exec. Officer | 1968 |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | CFO & Company Sec. | 1959 |
| Mr. David Lyon | Head of Marketing | NA |
| Dr. Dan Ruben Peres | Chief Medical Officer | 1976 |
| Mr. Flavio Palumbo | Chief Commercial Officer | NA |
| Mr. Steven George Lydeamore CPA, M.B.A. | Chief Executive Officer | 1968 |
| Mr. Flavio Palumbo | Chief Commercial Officer | 1974 |
| Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. | CFO & Company Secretary | 1959 |
| Dr. Jerry Kanellos Ph.D. | Chief Scientific Officer | 1961 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.93%
Communication Services
+1.45%
Consumer Cyclical
+2.28%
Consumer Defensive
+1.65%
Energy
-2.90%
Financial Services
+1.30%
Financials
-6.24%
Healthcare
+1.92%
Industrials
-0.05%
Real Estate
+1.24%
Technology
+0.07%
Utilities
+0.64%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...